Systematic review and meta-analysis of Saccharomyces boulardii in adult patients

Table 4 Randomized, controlled trials for acute disease conditions using S. boulardii

Ref.	Treatment groups	Study population	Daily dose: cfu/d (mg/d)	Duration of treatment	Follow-up(wk)	Outcome in probiotic	Outcome in controls
	Helicobacter pylori
Cremonini et al[134]	S. boulardii (Codex, SmithKine Beecham, Italy) vs placebo vs LGG vs mix (L acid and Bifid lactis)	85 asymptomatic carriers H. pylori 22 SB and 21 placebo; all received triple therapy	5 × 109 (nr)	2 wk	2	Eradicated in: 17/21 (81%) same for LGG and mix	Placebo, 16/20 (80%)
						Any symptoms: 4/21 (19%)a	Any symptoms: 12/20 (60%)
Cindoruk et al[42]	S. boulardii (Reflor, Turkey) vs placebo	124 adults with H. pylori dyspepsia, all received triple therapy	2 × 1010 (1000 mg)	2 wk	6	Eradication 44/62 (71%)	Eradication 37/62 (59.7%)
						Epigastric distress: 9 (14.5%)a	Distress: 27 (43.5%)
	Acute adult diarrheas
Hochter et al[169]	S. boulardii vs placebo	92 German outpatient adults	8 × 109 (300-600 mg)	8 d	0	Diarrhea score reduction: -17.2 + 6.8a	Score: -13.6 + 8.7
Mansour- ghanaei et al[51]	S. boulardii (UltraLevure, France) vs placebo. Both groups got metro and lodoquinol	57 enrolled, 54 done; adults with E. histolytica amoebic dysentery	1.5 × 1010 (750 mg)	10 d	4	Cured: 27/27 (100%)a	Cured: 5/27 (19%)
	Enteral feeding-related diarrhea
Tempe et al[61]	S. boulardii vs placebo	40 adults in ICU	1 × 1010 (nr)	11-21 d	0	34/389 days of diarrhea (8.7%)a	63/373 days of diarrhea (16.9%)
Schlotterer et al[171]	S. boulardiivs placebo	20 enrolled, 18 done, burnt adults 18-70 yr	4 × 1010 (2000 mg)	8-28 d	0	3/204 days of diarrhea (1.5%)a	19/208 days of diarrhea (9.1%)
Bleichner et al[39]	S. boulardii vs placebo	131 enrolled, 128 done, adults in ICU	4 × 1010 (2000 mg)	3 wk	0	50/648 days of diarrhea (7.7%)a	87/683 days of diarrhea (12.7%)
	Traveler’s diarrhea
Kollaritsch et al[175]	S. boulardii vs placebo	832 Austrian tourists to hot climates	2 × 109 (250 mg)	5 d before trip and mean 21 d trip	0	143/426 (34%)a	173/406 (43%)
Kollaritsch et al[175]	S. boulardii vs placebo	805 Austrian tourists to hot climates	5 × 109 (500 mg)	5 d before trip and mean 21 d trip	0	127/399 (32%)a	173/406 (43%)
Kollaritsch et al[49]	S. boulardii vs placebo	713 Austrian tourists to hot climates	2 × 109 (250 mg)	5 d before trip and mean 21 d trip	0	121/352 (34%)a	141/361 (39%)
Kollaritsch et al[49]	S. boulardii vs placebo	664 Austrian tourists to hot climates	2 × 1010 (1000 mg)	5 d before trip and mean 21 d trip	0	87/303 (29%)a	141/361 (39%)
Bruns et al[176]	S. cerevisiae Hansen (CBS 5926) vs active treatment1	60 tourists in Tunisia with traveler’s diarrhea, 43 done	1.0 × 1010 (600 mg)	5 d	0	Duration diarrhea 2.1 d	1.4 days of diarrheaa

^aP < 0.05, probiotic vs controls;

¹Strain currently known as S. boulardii.